SI1949915T1 - Postopek in sistem za odstranitev topnih TNFR1, TNFR2 in IL2R pri pacientih - Google Patents

Postopek in sistem za odstranitev topnih TNFR1, TNFR2 in IL2R pri pacientih

Info

Publication number
SI1949915T1
SI1949915T1 SI200531626T SI200531626T SI1949915T1 SI 1949915 T1 SI1949915 T1 SI 1949915T1 SI 200531626 T SI200531626 T SI 200531626T SI 200531626 T SI200531626 T SI 200531626T SI 1949915 T1 SI1949915 T1 SI 1949915T1
Authority
SI
Slovenia
Prior art keywords
il2r
tnfr2
patients
remove soluble
soluble tnfr1
Prior art date
Application number
SI200531626T
Other languages
English (en)
Inventor
Rigdon M Lentz
Original Assignee
Biopheresis Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopheresis Technologies, Inc. filed Critical Biopheresis Technologies, Inc.
Publication of SI1949915T1 publication Critical patent/SI1949915T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3403Regulation parameters
    • A61M1/3406Physical characteristics of the filtrate, e.g. urea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3482Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A61M1/3489Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents by biological cells, e.g. bioreactor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687Chemical treatment
    • A61M1/3689Chemical treatment by biological cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • External Artificial Organs (AREA)
SI200531626T 2004-04-30 2005-04-29 Postopek in sistem za odstranitev topnih TNFR1, TNFR2 in IL2R pri pacientih SI1949915T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56674104P 2004-04-30 2004-04-30
EP08007944A EP1949915B1 (en) 2004-04-30 2005-04-29 Method and system to remove soluble TNFR1, TNFR2, and IL2R in patients

Publications (1)

Publication Number Publication Date
SI1949915T1 true SI1949915T1 (sl) 2012-12-31

Family

ID=35320738

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531626T SI1949915T1 (sl) 2004-04-30 2005-04-29 Postopek in sistem za odstranitev topnih TNFR1, TNFR2 in IL2R pri pacientih

Country Status (17)

Country Link
US (6) US20050265996A1 (sl)
EP (2) EP1740209A2 (sl)
JP (1) JP2008511340A (sl)
CN (1) CN1980696B (sl)
AU (2) AU2005240082B2 (sl)
CA (1) CA2565215C (sl)
CY (1) CY1113345T1 (sl)
DK (1) DK1949915T3 (sl)
ES (1) ES2393637T3 (sl)
HK (1) HK1125026A1 (sl)
IL (2) IL178845A (sl)
IN (1) IN2009DN07374A (sl)
PL (1) PL1949915T3 (sl)
PT (1) PT1949915E (sl)
RU (1) RU2378016C2 (sl)
SI (1) SI1949915T1 (sl)
WO (1) WO2005107802A2 (sl)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
AU2005240082B2 (en) * 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
AU2005269820B2 (en) * 2004-07-22 2009-03-26 Early Detection Llc Methods for diagnosis using anti-cytokine receptor antibodies
US7918863B2 (en) * 2005-06-24 2011-04-05 Conceptus, Inc. Minimally invasive surgical stabilization devices and methods
EP1951336A2 (en) * 2005-07-18 2008-08-06 The Trustees Of Boston University Method to inhibit proliferation and growth of metastases
CA2644855C (en) * 2006-03-09 2019-11-19 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
AU2008293431B2 (en) * 2007-08-31 2013-07-04 Cytopherx, Inc. Selective cytopheresis devices and related methods thereof
JP2009178523A (ja) * 2008-02-01 2009-08-13 Kaneka Corp 可溶性腫瘍壊死因子受容体の吸着材、吸着方法および吸着装置
US8753690B2 (en) * 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2567692B1 (en) 2008-02-27 2016-04-06 Biomet Biologics, LLC Use of a device for obtaining interleukin-1 receptor antagonist rich solutions
US8905760B2 (en) * 2008-11-04 2014-12-09 Duane C. Keller Methods and systems for progressively treating and controlling oral periopathogens causing systemic inflammations
US8758287B2 (en) 2008-11-12 2014-06-24 Marv Enterprises, LLC Utilization of stents for the treatment of blood borne carcinomas
JP5249737B2 (ja) * 2008-12-10 2013-07-31 旭化成メディカル株式会社 血液からウイルス及びサイトカインを除去するシステム
US8454547B2 (en) 2009-02-25 2013-06-04 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
WO2010107789A1 (en) * 2009-03-17 2010-09-23 Marv Enterprises Llc Sequential extracorporeal treatment of bodily fluids
JP5844258B2 (ja) 2009-08-27 2016-01-13 バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニーBiomet Biologics, Llc インターロイキン−1受容体アンタゴニストの生産のための植込み型装置
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
EP2569253A4 (en) * 2010-05-14 2013-10-02 Beth Israel Hospital EXTRACORPOREAL DEVICES AND METHODS FOR TREATING PREGNANCY COMPLICATIONS
WO2012030593A2 (en) 2010-09-03 2012-03-08 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
CA2814586C (en) 2010-10-15 2024-01-30 Cytopherx, Inc. Cytopheretic cartridge and use thereof
JP2014503187A (ja) 2010-10-29 2014-02-13 ノクソン ファーマ エージー 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用
US20130131423A1 (en) * 2011-04-12 2013-05-23 Tianxin Wang Methods to detect and treat diseases
US9867923B2 (en) 2011-05-09 2018-01-16 University Of Miami Reducing soluble urokinase receptor in the circulation
US9138343B2 (en) 2011-05-31 2015-09-22 Bayer Healthcare Llc Tip protector sleeve
WO2012163544A1 (en) 2011-06-01 2012-12-06 Biopheresis Technologies, Inc. Removal of soluble tumor necrosis factor receptor 2 (stnfr2)
US8792693B2 (en) * 2011-07-09 2014-07-29 Gauss Surgical System and method for estimating extracorporeal blood volume in a physical sample
US10426356B2 (en) 2011-07-09 2019-10-01 Gauss Surgical, Inc. Method for estimating a quantity of a blood component in a fluid receiver and corresponding error
CA2852220A1 (en) 2011-10-14 2013-07-18 Cytopherx, Inc. Cartridge and method for increasing myocardial function
US9549953B2 (en) * 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
US8764695B2 (en) * 2012-09-28 2014-07-01 Isaac Eliaz Reduction of galectin-3 levels by plasmapheresis
US20150027950A1 (en) * 2012-03-27 2015-01-29 Marv Enterprises, LLC Treatment for atherosclerosis
EP2850559B1 (en) 2012-05-14 2021-02-24 Gauss Surgical, Inc. System and method for estimating a quantity of a blood component in a fluid canister
CN104661582B (zh) 2012-05-14 2018-07-27 高斯外科公司 处理患者失血的系统与方法
WO2013179143A2 (en) 2012-06-01 2013-12-05 Biopheresis Technologies, Inc. Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
EP2970490A4 (en) 2013-03-15 2017-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
JP6513668B2 (ja) * 2013-08-12 2019-05-15 ヘルス リサーチ インコーポレイテッドHealth Research, Inc. 前立腺癌のバイオマーカー
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
EP3086870B1 (en) * 2013-12-27 2019-01-02 Eliaz Therapeutics, Inc. Plasmapheresis device
US20170038382A1 (en) * 2014-01-24 2017-02-09 Ntercept, Llc Methods and compositions for immune dis-inhibition
EA035898B1 (ru) * 2014-10-03 2020-08-28 НАНОТИКС, ЭлЭлСи Композиции и способы для ингибирования биологической активности растворимых биомолекул
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
EP3274010B1 (en) * 2015-03-27 2019-10-02 Eliaz Therapeutics, Inc. Patient selective apheresis
CN104815360A (zh) * 2015-04-14 2015-08-05 复旦大学 循环肿瘤细胞过滤治疗仪
WO2016187071A1 (en) 2015-05-15 2016-11-24 Gauss Surgical, Inc. Systems and methods for assessing fluids from a patient
WO2016187072A1 (en) 2015-05-15 2016-11-24 Gauss Surgical, Inc. Methods and systems for characterizing fluids from a patient
WO2016187070A1 (en) 2015-05-15 2016-11-24 Gauss Surgical, Inc. Method for projecting blood loss of a patient during a surgery
KR20180034619A (ko) 2015-07-29 2018-04-04 나노틱스 엘엘씨 가용성 생체분자를 소거하기 위한 모듈 조성물 및 이와 관련된 방법
EP3374399A1 (en) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
EP3393539B1 (en) 2015-12-23 2023-12-27 Gauss Surgical, Inc. System and method for estimating an amount of a blood component in a volume of fluid
JP6934253B2 (ja) 2015-12-23 2021-09-15 ガウス サージカル, インコーポレイテッドGauss Surgical, Inc. 外科織物内の血液構成要素の量の評価方法
DE102016106510A1 (de) * 2016-04-08 2017-10-12 ToposNomos Ltd. Verfahren und Vorrichtung zum extrakorporalen Entfernen von pathogenen und/oder überzähligen Bestandteilen aus einer Zellprobe eines Patienten
CN110088137A (zh) 2016-10-19 2019-08-02 诺瓦罗技科斯生物科技有限公司 针对mica和micb蛋白的抗体
WO2018125812A1 (en) 2017-01-02 2018-07-05 Gauss Surgical, Inc. Tracking surgical items with prediction of duplicate imaging of items
WO2018129207A1 (en) 2017-01-04 2018-07-12 Nanotics, Llc Methods for assembling scavenging particles
US11229368B2 (en) 2017-01-13 2022-01-25 Gauss Surgical, Inc. Fluid loss estimation based on weight of medical items
WO2019053031A1 (en) * 2017-09-13 2019-03-21 Bavarian Immunology Association GmbH PURIFIED BLOOD FOR USE IN ANTICANCER THERAPY
EP3735281A4 (en) 2018-01-05 2022-03-02 Path Ex, Inc. DEVICE FOR THE CAPTURE AND REMOVAL OF DISEASE MATERIAL FROM FLUIDS
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
US20210382035A1 (en) * 2018-10-25 2021-12-09 Tl Genomics Inc. Pretreatment of blood for classifying blood cells using microchannel
US20220002423A1 (en) * 2018-11-15 2022-01-06 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
CN113677429B (zh) 2019-04-26 2023-08-18 东丽株式会社 可溶性肿瘤坏死因子受体的吸附材料
CN114096278A (zh) * 2019-05-07 2022-02-25 英谬免疫股份有限公司 通过体外单采血增加对检查点抑制剂的反应
WO2021203144A1 (en) * 2020-04-02 2021-10-07 Nuwellis, Inc. Multi-stage blood filtration
US11957825B2 (en) 2021-06-17 2024-04-16 Immunicom Inc. Modified TNF as a capture ligand
CN116492991B (zh) * 2023-04-20 2024-02-23 江苏恰瑞生物科技有限公司 可清除血液中TNF-α的血液灌流器填料制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) * 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US5643732A (en) * 1971-05-20 1997-07-01 Strahilevitz; Meir Immunological assay methods
US4189470A (en) * 1973-01-30 1980-02-19 Bio-Response, Inc. Method for the continuous removal of a specific antibody from the lymph fluid in animals and humans
US4116589A (en) * 1977-04-15 1978-09-26 Avco Corporation Extracorporeal pulsatile blood pump comprised of side by side bladders
US4191182A (en) * 1977-09-23 1980-03-04 Hemotherapy Inc. Method and apparatus for continuous plasmaphersis
USRE31688E (en) * 1977-09-23 1984-09-25 Hemotherapy, Inc. Method and apparatus for continuous plasmapheresis
US4439332A (en) * 1978-08-14 1984-03-27 American Cyanamid Company Stable emulsion copolymers of acrylamide and ammonium acrylate for use in enhanced oil recovery
US4350156A (en) * 1980-05-29 1982-09-21 Japan Foundation For Artificial Organs Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4605394A (en) * 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
US4512763A (en) * 1981-05-04 1985-04-23 Gamma Medical Products, Inc. Method and apparatus for selective removal of constituents of blood
US4664913A (en) * 1982-05-24 1987-05-12 Xoma Corporation Method for treating plasma for transfusion
US4634417A (en) * 1982-12-06 1987-01-06 Georgetown University Process for treatment of tumors and apparatus therefor
US4614513A (en) * 1984-08-13 1986-09-30 Fred Hutchinson Cancer Research Center Method and apparatus for treatment to remove immunoreactive substances from blood
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
US4801449A (en) * 1985-01-11 1989-01-31 Imre Corporation Method for treatment of Kaposi's sarcoma
US5037649A (en) * 1985-01-11 1991-08-06 Imre Corporation Method for treatment of HIV-infected patients
US4863611A (en) * 1987-04-30 1989-09-05 Massachusetts Institute Of Technology Extracorporeal reactors containing immobilized species
US4865841A (en) * 1987-10-23 1989-09-12 Imre Corporation Methods and compositions for transient elimination of humoral immune antibodies
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
JPH07106219B2 (ja) * 1988-08-02 1995-11-15 宇部興産株式会社 インターロイキン2レセプターの除去装置およびそれを備えた血液体外循環装置
US5078673A (en) * 1988-11-14 1992-01-07 Neorx Corporation Selective removal of radiolabeled antibodies
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP0939121B2 (de) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
DE4006269A1 (de) * 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
US6432405B1 (en) * 1991-03-15 2002-08-13 Duke University Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies
ATE232730T1 (de) * 1991-08-23 2003-03-15 Alberta Res Council Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten
DE4331358A1 (de) * 1992-10-12 1994-04-14 Braun Melsungen Ag Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten
CA2149881A1 (en) * 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
US5910252A (en) * 1993-02-12 1999-06-08 Cobe Laboratories, Inc. Technique for extracorporeal treatment of blood
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5626843A (en) * 1993-02-26 1997-05-06 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5437861A (en) * 1993-03-16 1995-08-01 Applied Immune Sciences, Inc. Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome
AU680897B2 (en) * 1993-03-16 1997-08-14 Aventis Pharmaceuticals Inc. Removal of selected factors from whole blood or its components and prevention and treatment of septic shock symdrome
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5753227A (en) * 1993-07-23 1998-05-19 Strahilevitz; Meir Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
CN1137257A (zh) * 1993-11-12 1996-12-04 Idv经营爱尔兰公司 倾倒至少两种不同液体的倾倒器
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5705615A (en) * 1994-10-06 1998-01-06 Beth Israel Deaconess Medical Center Antibodies specific for HTm4
CA2167138C (en) * 1995-01-17 2000-10-31 Keigo Arimoto Splicing gauge
CA2167872C (en) * 1995-01-27 2007-04-03 Masaru Nakatani Adsorbent for removing interleukins and tumor necrosis factor, and process for removing the same
US6428790B1 (en) * 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
DE19538641C2 (de) * 1995-10-05 2000-09-21 Privates Inst Bioserv Gmbh Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren für deren Herstellung
EP0862444B2 (en) * 1995-11-15 2014-04-09 Edwards Lifesciences Corporation Treatment of dilated cardiomyopathy by removal of autoantibodies
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US5869047A (en) * 1996-10-22 1999-02-09 Blake Laboratories, Inc. Methods for therapeutically treating immunocomprised persons
US6245038B1 (en) * 1997-01-07 2001-06-12 Helmut Borberg Method for treatment of ophthalmological diseases
US6221614B1 (en) * 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
US6197289B1 (en) * 1997-07-01 2001-03-06 Terumo Cardiovascular Systems Corporation Removal of biologically active agents
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6287516B1 (en) * 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
US6528057B1 (en) * 1998-08-31 2003-03-04 Julian L. Ambrus Method for removal of HIV and other viruses from blood
JP4638986B2 (ja) * 1998-10-16 2011-02-23 テルモ メディカル コーポレイション 血液処理装置
WO2000029019A1 (en) * 1998-11-18 2000-05-25 G.D. Searle & Co. Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
JP2002533169A (ja) * 1998-12-29 2002-10-08 オキュロジックス コーポレイション レオロジー的処置方法および関連するアフェレーシスシステム
US6982089B2 (en) * 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
CA2369576C (en) * 1999-04-23 2005-07-05 William Frederick Weitzel Extracorporeal circuit and related methods
US6774102B1 (en) * 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
ATE445414T1 (de) * 1999-11-10 2009-10-15 Biopheresis Technologies Inc Verfahren und system zur entfernung von zytokininhibitoren in patienten
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US6890315B1 (en) * 2000-05-23 2005-05-10 Chf Solutions, Inc. Method and apparatus for vein fluid removal in heart failure
JP2002325837A (ja) * 2000-06-15 2002-11-12 Nefuronetto:Kk 自動血液透析装置
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US20030148404A1 (en) * 2000-07-27 2003-08-07 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US20020058031A1 (en) * 2000-09-19 2002-05-16 Tung Hsiaoho Edward Methods for preparing diagnostic reagents using antibody preparation
US20020107469A1 (en) * 2000-11-03 2002-08-08 Charles Bolan Apheresis methods and devices
US20020086276A1 (en) * 2000-12-28 2002-07-04 Srivastava Pramod K. Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands
US6761700B2 (en) * 2001-02-09 2004-07-13 Orqis Medical Corporation Extra-corporeal vascular conduit
US20020114728A1 (en) * 2001-02-13 2002-08-22 Kulish Victor V. Electronic Sterilizer
US6878127B2 (en) * 2001-04-10 2005-04-12 Renaltech International, Llc Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US6607501B2 (en) * 2001-05-14 2003-08-19 Reynolds G. Gorsuch Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications
US6685664B2 (en) * 2001-06-08 2004-02-03 Chf Solutions, Inc. Method and apparatus for ultrafiltration utilizing a long peripheral access venous cannula for blood withdrawal
AU2002321760B9 (en) * 2001-07-20 2008-06-12 Absorber, Ab Blood group antigen fusion polypeptides and methods of use thereof
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
CA2457564C (en) * 2001-10-05 2009-04-07 Surmodics, Inc. Particle immobilized coatings and uses thereof
AU2005240082B2 (en) * 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals

Also Published As

Publication number Publication date
US20080145333A1 (en) 2008-06-19
AU2009227872B2 (en) 2011-06-16
CN1980696A (zh) 2007-06-13
IN2009DN07374A (sl) 2015-07-24
RU2378016C2 (ru) 2010-01-10
US20150231233A1 (en) 2015-08-20
IL201888A (en) 2011-10-31
CA2565215A1 (en) 2005-11-17
US20050265996A1 (en) 2005-12-01
AU2009227872A1 (en) 2009-11-12
WO2005107802A3 (en) 2006-03-30
CA2565215C (en) 2014-04-15
HK1125026A1 (en) 2009-07-31
DK1949915T3 (da) 2012-11-26
CY1113345T1 (el) 2016-06-22
ES2393637T3 (es) 2012-12-26
IL178845A0 (en) 2007-03-08
US20130251672A1 (en) 2013-09-26
IL201888A0 (en) 2010-06-16
AU2005240082A1 (en) 2005-11-17
PL1949915T3 (pl) 2013-04-30
JP2008511340A (ja) 2008-04-17
EP1949915A3 (en) 2009-08-19
PT1949915E (pt) 2012-11-27
CN1980696B (zh) 2012-09-26
IL178845A (en) 2011-06-30
AU2005240082B2 (en) 2009-07-23
RU2006142328A (ru) 2008-06-20
US20110129441A1 (en) 2011-06-02
EP1949915B1 (en) 2012-08-22
US20120328562A1 (en) 2012-12-27
EP1740209A2 (en) 2007-01-10
EP1949915A2 (en) 2008-07-30
WO2005107802A2 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
HK1125026A1 (en) Method and system to remove soluble tnfr1, tnfr2, and il2r in patients
EP1804889A4 (en) PATIENT HYDRATION SYSTEM AND METHOD
ZA200703395B (en) Transaction system and method
EP1766596A4 (en) SYSTEM AND METHOD FOR MEDICAL SIMULATION
IL181892A0 (en) Method and system for combined ultrasound treatment
IL181895A0 (en) System and method for variable depth ultrasound treatment
TWI350286B (en) Alkylpiperazine- and alkylhomopiperazine-carboxylate derivatives, their preparation and their application in therapy
EP1795045A4 (en) ACOUSTIC TRANSPARENT OCCLUSION REDUCTION SYSTEM AND METHOD
EP1810710A4 (en) SYSTEM FOR IMPROVING SLEEPING AND METHOD FOR IMPROVING SLEEPING
EP1733772A4 (en) GAME METHOD AND GAME SYSTEM
EP1733310A4 (en) SYSTEM AND METHOD FOR THE PRODUCTION OF ORTHESES
EP2056899A4 (en) DEVICES, METHODS AND SYSTEMS FOR ESTABLISHING ADDITIONAL BLOOD FLOW IN THE CIRCULATORY SYSTEM
EP1773317A4 (en) METHOD OF TREATING OVERLOADING DISEASE DUE TO ACCUMULATION OF GLYCOGENES OR POLYSACCHARIDES
EP1571910A4 (en) CYTOTHERAPEUTIC AGENTS, CYTOTHERAPEUTIC UNITS AND METHODS OF TREATMENT IN WHICH THEY INTERVENE
WO2007022245A3 (en) Patient compliance system and method to promote patient compliance
GB0409806D0 (en) Nerve blocking method and system
EP1692389A4 (en) SYSTEM AND METHOD FOR RECIRCULATING CARTER GAS
EP1799302A4 (en) METHOD AND DEVICES FOR THE NIERENNERVENBLOCKADE
GB0424089D0 (en) Trading system and method
EP1781386A4 (en) GAME SHOW SYSTEM AND METHOD FOR ITS IMPLEMENTATION
EP1767547A4 (en) FLUOR-CONTAINING COPOLYMER-CONTAINING SOIL RELEASE AGENT AND METHOD OF MANUFACTURING THEREOF
EP1707104A4 (en) ENDOSCOPE, ENDOSCOPY SYSTEM AND FILTER UNIT
HK1103904A1 (en) System and method for facilitating communications between two parties
IL184094A0 (en) Novel galenic system for active principle transport, preparation method and use
EP1886420A4 (en) METHOD AND SYSTEM FOR INTERRUPTED SPEECH RECOVERY IN ALTERNATE CONVERSATION OVER A CELLULAR NETWORK